All Updates

All Updates

icon
Filter
Partnerships
Dewpoint Therapeutics partners with Novo Nordisk to treat insulin resistance and diabetic complications
AI Drug Discovery
Mar 22, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Mar 22, 2023

Dewpoint Therapeutics partners with Novo Nordisk to treat insulin resistance and diabetic complications

Partnerships

  • Massachusetts-based AI biotechnology company Dewpoint Therapeutics has entered a research and development partnership with pharmaceutical manufacturing company Novo Nordisk to utilize Dewpoint's drug discovery platform in identifying potential drug candidates for the treatment of insulin resistant and diabetic complications.

  • The partnership aims to identify potential small molecule drugs against new condensate targets that might play a role in insulin resistance, a primary cause of type 2 diabetes and metabolic syndrome. Novo Nordisk may also utilize its internal capabilities to explore non-small molecule drugs with identified condensates as potential targets.

  • Under the terms of the partnership, Dewpoint will receive USD 55 million in near-term payments, which includes an initial payment, funds for research, and potential milestones for two programs. Additionally, Dewpoint is also able to make up to USD 690 million based on further clinical and commercial milestones, as well as royalties for two products.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.